Loretta Gammaitoni

3.3k total citations
66 papers, 2.3k citations indexed

About

Loretta Gammaitoni is a scholar working on Oncology, Immunology and Hematology. According to data from OpenAlex, Loretta Gammaitoni has authored 66 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 23 papers in Immunology and 18 papers in Hematology. Recurrent topics in Loretta Gammaitoni's work include CAR-T cell therapy research (23 papers), Hematopoietic Stem Cell Transplantation (15 papers) and Immune Cell Function and Interaction (15 papers). Loretta Gammaitoni is often cited by papers focused on CAR-T cell therapy research (23 papers), Hematopoietic Stem Cell Transplantation (15 papers) and Immune Cell Function and Interaction (15 papers). Loretta Gammaitoni collaborates with scholars based in Italy, United States and Belarus. Loretta Gammaitoni's co-authors include Massimo Aglietta, Franca Fagioli, Wanda Piacibello, M. C. Nucci, F Sanavio, Giuliana Cavalloni, Dario Sangiolo, Stefania Bruno, Alessandra Danè and Monica Gunetti and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Loretta Gammaitoni

66 papers receiving 2.3k citations

Peers

Countries citing papers authored by Loretta Gammaitoni

Since Specialization

Citations

This map shows the geographic impact of Loretta Gammaitoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Loretta Gammaitoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Loretta Gammaitoni more than expected).

Fields of papers citing papers by Loretta Gammaitoni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Loretta Gammaitoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Loretta Gammaitoni. The network helps show where Loretta Gammaitoni may publish in the future.

Co-authorship network of co-authors of Loretta Gammaitoni

This figure shows the co-authorship network connecting the top 25 collaborators of Loretta Gammaitoni. A scholar is included among the top collaborators of Loretta Gammaitoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Loretta Gammaitoni. Loretta Gammaitoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Baseline Values of Circulating IL-6 and TGF-β Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment 2023 ·Cancers ·Marco Merlano, (unknown), Nerina Denaro, (unknown), Danilo Galizia, Dario Sangiolo, Loretta Gammaitoni, Erika Fiorino, (unknown), Paolo Bossi, Lisa Licitra, Ornella Garrone	4
2	Role of fluctuations in epidemic resurgence after a lockdown 2021 ·Scientific Reports ·I. Neri, Loretta Gammaitoni	7
3	BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody 2018 ·Clinical Cancer Research ·Martina Sanlorenzo, Igor Vujic, (unknown), Mauro Novelli, Loretta Gammaitoni, Lidia Giraudo, Marco Macagno, Valeria Leuci, Ramona Rotolo, (unknown), Marco Basiricò, Pietro Quaglino, Maria Teresa Fierro, Silvia Giordano, Maria Sibilia, Fabrizio Carnevale‐Schianca, Massimo Aglietta, Dario Sangiolo	30
4	Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR 2018 ·PLoS ONE ·Caterina Peraldo‐Neia, Giuliana Cavalloni, Elisabetta Fenocchio, Celeste Cagnazzo, Loretta Gammaitoni, Stefano Cereda, Guglielmo Nasti, Maria Antonietta Satolli, Giuseppe Aprile, Michele Reni, Antonio Avallone, Rosella Spadi, Tiziana Venesio, Vittoria Martin, Claudio Doglioni, Milo Frattini, Massimo Aglietta, Francesco Leone	13
5	Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives 2015 ·Expert Opinion on Biological Therapy ·Martina Sanlorenzo, Igor Vujic, (unknown), Pietro Quaglino, Maria Teresa Fierro, Loretta Gammaitoni, Fabrizio Carnevale‐Schianca, Massimo Aglietta, Dario Sangiolo	6
6	Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy 2014 ·Anti-Cancer Agents in Medicinal Chemistry ·Valeria Leuci, Giulia Mesiano, Loretta Gammaitoni, Maja Todorovic, Lidia Giraudo, Fabrizio Carnevale‐Schianca, Massimo Aglietta, Dario Sangiolo	2
7	Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features 2013 ·Clinical Cancer Research ·Loretta Gammaitoni, Lidia Giraudo, Valeria Leuci, Maja Todorovic, Giulia Mesiano, Franco Picciotto, Alberto Pisacane, Alessandro Zaccagna, (unknown), Susanna Gallo, Daniela Caravelli, (unknown), Tiziana Venesio, Antonella Balsamo, Ymera Pignochino, Giovanni Grignani, Fabrizio Carnevale‐Schianca, Massimo Aglietta, Dario Sangiolo	80
8	The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models 2013 ·Clinical Cancer Research ·Ymera Pignochino, Carmine Dell’Aglio, Marco Basiricò, Federica Capozzi, Marco Soster, Serena Marchiò, Stefania Bruno, Loretta Gammaitoni, Dario Sangiolo, (unknown), Lorenzo D’Ambrosio, Franca Fagioli, Stefano Ferrari, Marco Alberghini, Piero Picci, Massimo Aglietta, Giovanni Grignani	91
9	Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas 2012 ·Molecular Cancer Therapeutics ·Giuliana Cavalloni, Caterina Peraldo‐Neia, Ivana Sarotto, Loretta Gammaitoni, Giorgia Migliardi, Marco Soster, Serena Marchiò, Massimo Aglietta, Francesco Leone	13
10	Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors 2012 ·Expert Opinion on Biological Therapy ·Giulia Mesiano, Maja Todorovic, Loretta Gammaitoni, Valeria Leuci, Lidia Giraudo, Fabrizio Carnevale‐Schianca, Franca Fagioli, Wanda Piacibello, Massimo Aglietta, Dario Sangiolo	122
11	HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib 2010 ·Breast Cancer Research and Treatment ·Giorgio Valabrega, (unknown), Giuliana Cavalloni, Gianluca Zaccarello, Annalisa Petrelli, Giorgia Migliardi, Andrea Milani, Caterina Peraldo‐Neia, Loretta Gammaitoni, Anna Sapino, Carla Pecchioni, Aldo Moggio, Silvia Giordano, Massimo Aglietta, Filippo Montemurro	35
12	Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways 2009 ·Molecular Cancer ·Ymera Pignochino, Giovanni Grignani, Giuliana Cavalloni, Manuela Motta, Marta Tapparo, Stefania Bruno, Alessia Bottos, Loretta Gammaitoni, Giorgia Migliardi, Giovanni Camussi, Marco Alberghini, Bruno Torchio, Stefano Ferrari, Federico Bussolino, Franca Fagioli, Piero Picci, Massimo Aglietta	146
13	Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab 2008 ·Anti-Cancer Drugs ·Giuliana Cavalloni, Ivana Sarotto, Ymera Pignochino, Loretta Gammaitoni, Giorgia Migliardi, Luca Giuseppe Sgrò, Wanda Piacibello, Mauro Risio, Massimo Aglietta, Francesco Leone	7
14	Refreezing of cord blood hematopoietic stem cells for allogenic transplantation: in vitro and in vivo validation of a clinical phase I/II protocol in European and Italian Good Manufacturing Practice conditions 2008 ·Experimental Hematology ·Monica Gunetti, Ivana Ferrero, Deborah Rustichelli, Massimo Berger, Loretta Gammaitoni, Fabio Timeus, Wanda Piacibello, Massimo Aglietta, Franca Fagioli	15
15	Ex vivo expansion of human adult stem cells capable of primary and secondary hemopoietic reconstitution 2003 ·Experimental Hematology ·Loretta Gammaitoni, Stefania Bruno, F Sanavio, Monica Gunetti, Órit Kollet, Giuliana Cavalloni, Michele Falda, Franca Fagioli, Tsvee Lapidot, Massimo Aglietta, Wanda Piacibello	72
16	Negative Influence of IL3 on the Expansion of Human Cord Blood In Vivo Long-Term Repopulating Stem Cells 2000 ·Journal of Hematotherapy & Stem Cell Research ·Wanda Piacibello, Loretta Gammaitoni, Stefania Bruno, Monica Gunetti, Franca Fagioli, Giuliana Cavalloni, Massimo Aglietta	29
17	Negative influence of IL3 on the expansion of human cord blood in vivo long-term repopulating stem cells 2000 ·Stem Cells and Development ·Wanda Piacibello, Loretta Gammaitoni, Stefania Bruno, Monica Gunetti	1
18	Ex Vivo Expansion of Cord Blood Progenitors 1998 ·Vox Sanguinis ·Wanda Piacibello, F Sanavio, A Severino, L. Garetto, Alessandra Danè, Loretta Gammaitoni, Massimo Aglietta	13
19	Differential growth factor requirement of primitive cord blood hematopoietic stem cell for self-renewal and amplification vs proliferation and differentiation 1998 ·Leukemia ·Wanda Piacibello, F Sanavio, L. Garetto, A Severino, Alessandra Danè, Loretta Gammaitoni, Massimo Aglietta	111
20	GAS6, the ligand of Axl and Rse receptors, is expressed in hematopoietic tissue but lacks mitogenic activity. 1997 ·PubMed ·G. Avanzi, Margherita Gallicchio, Giuliana Cavalloni, Loretta Gammaitoni, Francesco Leone, A. Rosina, Renzo Boldorini, (unknown), Luigi Pegoraro, Brian Varnum, Massimo Aglietta	55

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact